IRVINE, Calif., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS FORWARD-IDE clinical trial, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Nellix® EndoVascular Aneurysm Sealing System ("Nellix EVAS System") for the endovascular repair of infrarenal abdominal aortic aneurysms. The EVAS FORWARD-IDE clinical trial is approved to enroll 180 patients at up to 30 centers in the U.S., Canada and Europe, of which approximately 25 will be in the U.S. The first procedure was performed by Professor Dittmar Boeckler, MD, a vascular surgeon at Heidelberg University Hospital in Germany.
Help employers find you! Check out all the jobs and post your resume.
